Lucemyra

Chemical Namelofexidine
Dosage FormTablet (oral; 0.18 mg)
Drug ClassReceptor agonists
SystemNervous
CompanyUS Worldmeds
Approval Year2018

Indication

  • Lucemyra is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Lucemyra (lofexidine) Prescribing Information2018US Worldmeds
Document TitleYearSource
Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review.2020Journal of the American Pharmacists Association
Opioid antagonists with minimal sedation for opioid withdrawal.2017The Cochrane Database of Systematic Reviews
Alphaâ‚‚-adrenergic agonists for the management of opioid withdrawal.2016The Cochrane Database of Systematic Reviews